<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Elisence – Phase 6: Global Medication Brain</title>

    <style>
        body {
            margin: 0;
            font-family: Arial, Helvetica, sans-serif;
            background-color: #08172a;
            color: #e8f4fc;
            line-height: 1.6;
        }

        /* ======= HEADER ======= */
        header {
            background-color: #020617;
            padding: 1.8rem 0;
            border-bottom: 1px solid #1e293b;
            box-shadow: 0 6px 20px rgba(0, 0, 0, 0.6);
        }

        .header-inner {
            max-width: 1100px;
            margin: 0 auto;
            padding: 0 1.5rem;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .brand-block {
            display: flex;
            flex-direction: column;
        }

        .brand-title {
            font-size: 1.4rem;
            font-weight: 700;
            letter-spacing: 0.14rem;
        }

        .brand-sub {
            font-size: 0.85rem;
            color: #60a5fa;
        }

        nav.main-nav {
            display: flex;
            gap: 1.8rem;
        }

        nav.main-nav a {
            color: #e2e8f0;
            text-decoration: none;
            font-size: 0.92rem;
            letter-spacing: 0.05rem;
            text-transform: uppercase;
        }

        nav.main-nav a:hover {
            color: #38bdf8;
            text-decoration: underline;
        }

        nav.main-nav a.active {
            color: #38bdf8;
            font-weight: 600;
        }

        /* ======= MAIN CONTENT ======= */
        main {
            max-width: 1100px;
            margin: 2.4rem auto 3.2rem auto;
            padding: 0 1.5rem;
        }

        h1 {
            font-size: 1.9rem;
            margin-bottom: 0.6rem;
            color: #38bdf8;
        }

        .phase-label {
            font-size: 0.82rem;
            text-transform: uppercase;
            letter-spacing: 0.12rem;
            color: #94a3b8;
            margin-bottom: 0.4rem;
        }

        .lead {
            font-size: 1rem;
            color: #cbd5f5;
            margin-bottom: 1.8rem;
        }

        .card {
            background: rgba(15, 23, 42, 0.95);
            border-radius: 18px;
            border: 1px solid #1e293b;
            box-shadow: 0 16px 50px rgba(0, 0, 0, 0.55);
            padding: 1.8rem 1.9rem;
            margin-bottom: 1.8rem;
        }

        .card h2 {
            margin-top: 0;
            margin-bottom: 0.8rem;
            font-size: 1.3rem;
            color: #7dd3fc;
        }

        .card h3 {
            margin-top: 1.1rem;
            margin-bottom: 0.5rem;
            font-size: 1.05rem;
            color: #bae6fd;
        }

        .card p {
            margin: 0.4rem 0;
            font-size: 0.95rem;
            color: #e5f2ff;
        }

        .card ul {
            margin: 0.5rem 0 0.2rem 1.2rem;
            padding-left: 0.4rem;
        }

        .card li {
            margin-bottom: 0.35rem;
            font-size: 0.94rem;
        }

        .tagline {
            font-size: 0.95rem;
            color: #93c5fd;
            margin-bottom: 0.5rem;
        }

        .subtle {
            font-size: 0.9rem;
            color: #94a3b8;
        }

        @media (max-width: 900px) {
            .header-inner {
                flex-direction: column;
                align-items: flex-start;
                gap: 0.8rem;
            }

            nav.main-nav {
                flex-wrap: wrap;
                gap: 1.1rem;
            }

            main {
                padding: 0 1.2rem;
            }

            .card {
                padding: 1.5rem 1.4rem;
            }
        }
    </style>
</head>

<body>

<header>
    <div class="header-inner">
        <div class="logo-section">
            <img src="elisence.png" alt="Elisence Logo" class="logo-img">
            <div class="logo-text">
                <h1>ELISENCE</h1>
                <p>Global Digital Health & Humanity Platform</p>
            </div>
        </div>

        <nav class="main-nav">
            <a href="index.html">Home</a>
            <a href="index.html#phases">Phases</a>
            <a href="about.html">About</a>
            <a href="story.html">Story</a>
            <a href="video.html">Videos</a>
            <a href="contact.html">Contact</a>
        </nav>
    </div>
</header>
<main>

    <div class="phase-label">PHASE 6</div>
    <h1>Global Medication Brain</h1>

    <p class="lead">
        Phase 6 is the multilingual, jurisdiction-aware, zero-trust <strong>Global Medication Brain</strong> of Elisence.
        It safely understands and structures medication behaviour across five languages, powering every major phase of
        the platform while staying legally compliant with NHS, FDA, EU MDR, and GCC regulations.
    </p>

    <!-- 1. WHAT PHASE 6 REALLY IS -->
    <section class="card">
        <h2>1. What Phase 6 Really Is (Honest, Precise)</h2>
        <p>
            Phase 6 is the “Global Medication Brain” of Elisence.
            It is not a medical diagnosis engine and not a drug-recommendation system.
            It is a strictly controlled, zero-trust semantic engine that <strong>understands</strong>,
            <strong>structures</strong>, and <strong>sanity-checks</strong> anything users say or type about medications.
        </p>
        <p>
            This phase converts natural human language (text or voice-transcribed speech)
            into a <strong>safe, structured medical event</strong> that downstream systems can trust.
        </p>
        <p>
            It is already fully built as a stable baseline, and is now evolving into a global drug-intelligence layer
            that will power:
        </p>
        <ul>
            <li>Diabetes</li>
            <li>Weight-Loss (GLP-1)</li>
            <li>Women+ Health</li>
            <li>AHE (Advanced Health Engine)</li>
            <li>Voice / Zero-Typing (Phase 13)</li>
            <li>Blind-Assist / Accessibility modules</li>
            <li>Clinician dashboards (future)</li>
        </ul>
    </section>

    <!-- 2. WHAT IS ALREADY BUILT -->
    <section class="card">
        <h2>2. What Is Already Built (Verifiable Today)</h2>
        <p>
            The current engine in Phase 6 is a real, working baseline. It includes:
        </p>

        <h3>2.1 Multilingual Input Normalization</h3>
        <ul>
            <li>Works in <strong>EN, FA, AR, TR, RO</strong></li>
            <li>Cleans text, fixes spacing, unifies digits, normalises casing</li>
            <li>Prepares tokens for downstream parsing</li>
        </ul>
        <p class="subtle">Implemented &amp; tested — screenshots, code &amp; logs available.</p>

        <h3>2.2 Spell-Correction &amp; Token Normalization</h3>
        <ul>
            <li>Advanced dictionaries for drug names (e.g., “monjaro”, “mounjaru” → “Mounjaro”)</li>
            <li>Correction of daily language mistakes across 5 languages</li>
        </ul>
        <p class="subtle">Implemented — in code.</p>

        <h3>2.3 Drug Detection (Deterministic)</h3>
        <ul>
            <li>Recognises Mounjaro, Ozempic, Wegovy, Metformin and other GLP-1/diabetes medications</li>
            <li>No hallucination; either a clear detection or <code>"no_match"</code></li>
        </ul>
        <p class="subtle">Implemented — in code.</p>

        <h3>2.4 Action Detection (take / stop / miss)</h3>
        <ul>
            <li>Multilingual intent engine with per-language lexicons</li>
            <li>Negation detection (e.g., “نزنم”, “لا”, “don’t”)</li>
            <li>Fully deterministic, no LLM involved</li>
        </ul>
        <p class="subtle">Implemented — in code.</p>

        <h3>2.5 Dose Parsing</h3>
        <ul>
            <li>Regex-based dose extraction (2.5mg, 5 mg, “دو و نیم میلی‌گرم”)</li>
            <li>Unit normalisation (“mg” unified across languages)</li>
        </ul>
        <p class="subtle">Implemented — in code.</p>

        <h3>2.6 Date Recognition</h3>
        <ul>
            <li>Recognises ISO dates, UK style, and numeric strings (YYYYMMDD)</li>
            <li>Rejects ambiguous dates under zero-trust rules</li>
        </ul>
        <p class="subtle">Implemented — in code.</p>

        <h3>2.7 Semantic Medication Event</h3>
        <p>
            Everything above is combined into a structured object:
        </p>
        <ul>
            <li>drug_name</li>
            <li>action</li>
            <li>dose</li>
            <li>date_iso</li>
            <li>warnings</li>
            <li>confidence</li>
            <li>uncertainty_reason</li>
            <li>audit / debug fields</li>
        </ul>
        <p class="subtle">
            This semantic event backbone is already integrated as a core part of Elisence.
        </p>

        <h3>2.8 Phase-Wide API (<code>smart_understand</code>)</h3>
        <ul>
            <li>The unified endpoint for all phases</li>
            <li>Used by Phase 5 (Elisa), Phase 13 (Voice), Phase 8 (AHE), Diabetes, GLP-1, Women+</li>
        </ul>
        <p class="subtle">
            Implemented as a stable, single source of truth for medication understanding.
        </p>
    </section>

    <!-- 3. ROADMAP -->
    <section class="card">
        <h2>3. What Phase 6 Will Become (Realistic Roadmap)</h2>
        <p>
            Phase 6 is on track to evolve into a global medication intelligence engine.
        </p>

        <h3>3.1 Ontology v1.0 (Next Step)</h3>
        <p>
            Introduction of a controlled drug-ontology with fields:
        </p>
        <ul>
            <li>drug_id, class, mechanism</li>
            <li>adult dose ranges</li>
            <li>regulatory categories (UK/EU/GCC)</li>
            <li>availability per country</li>
            <li>safety notes (never shown directly to users)</li>
        </ul>
        <p>
            This will make Elisence independent from proprietary drug databases used by Omada,
            Livongo, and Huma.
        </p>

        <h3>3.2 Sanity-Check Layer</h3>
        <p>
            Non-diagnostic rules to detect:
        </p>
        <ul>
            <li>unrealistic doses (e.g., “50 mg Mounjaro”)</li>
            <li>impossible frequencies</li>
            <li>contradictory statements</li>
        </ul>
        <p>
            Output is always safe and conservative:
            <br>
            → “Please review with a clinician.”
        </p>

        <h3>3.3 Candidate Drug Learning (Supervised Learning)</h3>
        <ul>
            <li>System detects unknown drug names mentioned repeatedly</li>
            <li>Stores them as candidates for clinical review</li>
            <li>Requires human clinical approval before activation</li>
        </ul>
        <p class="subtle">Zero-Trust and BBVP-compliant.</p>

        <h3>3.4 Global Class Mapping</h3>
        <p>
            Mapping each drug to:
        </p>
        <ul>
            <li>GLP-1 class</li>
            <li>SGLT2</li>
            <li>Insulins</li>
            <li>Obesity pharmacotherapy</li>
        </ul>
        <p class="subtle">
            General, non-diagnostic information only.
        </p>

        <h3>3.5 Multi-Phase Integration</h3>
        <p>
            Phase 6 becomes the single medication source of truth for:
        </p>
        <ul>
            <li>Weight / GLP-1 engine (Phase 3)</li>
            <li>Women+ (Phase 7)</li>
            <li>Diabetes &amp; AHE (Phase 8)</li>
            <li>Personality &amp; Voice (Phase 5 &amp; 13)</li>
            <li>Accessibility &amp; Blind-Assist</li>
        </ul>

        <h3>3.6 Cross-Market Regulatory Alignment</h3>
        <ul>
            <li>Non-Device CDS (FDA)</li>
            <li>Wellness / information layer (EU MDR)</li>
            <li>DCB0129 / 0160 risk controls (NHS)</li>
            <li>PDPL / Qatar / GCC residency support</li>
        </ul>
        <p>
            This ensures minimal regulatory friction and maximum safety.
        </p>
    </section>

    <!-- 4. LEGAL SAFETY -->
    <section class="card">
        <h2>4. Why This Phase Is Legally Safe</h2>
        <p>
            Phase 6 is intentionally designed <strong>not</strong> to cross into diagnosis or treatment.
        </p>

        <h3>4.1 NHS</h3>
        <ul>
            <li>Classified as a Health IT component</li>
            <li>No clinical decision-making</li>
            <li>Outputs are informational only</li>
            <li>Every inference is auditable</li>
            <li>Hazard log is maintained</li>
        </ul>

        <h3>4.2 FDA</h3>
        <ul>
            <li>Falls under “Non-Device Clinical Decision Support”</li>
            <li>User (clinician or patient) can independently evaluate the basis of the output</li>
            <li>No automated treatment recommendations</li>
        </ul>

        <h3>4.3 EU MDR</h3>
        <ul>
            <li>No standalone medical purpose</li>
            <li>Does not directly influence treatment decisions</li>
            <li>A future professional module can be isolated with its own MDR class</li>
        </ul>

        <h3>4.4 GCC</h3>
        <ul>
            <li>Data residency supported</li>
            <li>Strong PDPL alignment</li>
            <li>Non-diagnostic layer → no medical licensing required</li>
        </ul>

        <h3>4.5 Zero-Trust</h3>
        <ul>
            <li>Every input is treated as untrusted</li>
            <li>Low-confidence cases trigger clarification</li>
            <li>Never “guess” a drug or dose</li>
            <li>No silent assumptions</li>
        </ul>

        <h3>4.6 BBVP (Build-Back-Verify-Prove)</h3>
        <ul>
            <li><strong>Build</strong> – implement the feature</li>
            <li><strong>Back</strong> – create a rollback plan</li>
            <li><strong>Verify</strong> – tests, accuracy checks, fuzzing</li>
            <li><strong>Prove</strong> – evidence pack with SHA-256 hashes</li>
        </ul>
        <p>
            This is what makes Phase 6 regulator-ready.
        </p>
    </section>

    <!-- 5. VOICE SUPPORT -->
    <section class="card">
        <h2>5. How Phase 6 Supports Voice (Phase 13)</h2>
        <p>
            Phase 13 handles speech-to-text and high-level intent classification.
            Phase 6 interprets the medication content.
        </p>

        <p>
            Together they enable:
        </p>
        <ul>
            <li>“Elisa, I forgot my dose”</li>
            <li>“الیسا دیشب داروم رو نزدم”</li>
            <li>“Elisa, increase to 5 mg next week?” → flagged for clinical confirmation</li>
        </ul>

        <p>
            Noise handling:
        </p>
        <ul>
            <li>Phase 13 provides an STT confidence score</li>
            <li>If confidence &lt; threshold → Phase 6 asks for confirmation</li>
            <li>No uncontrolled interpretations (Zero-Trust preserved)</li>
        </ul>
    </section>

    <!-- 6. INVESTOR VALUE -->
    <section class="card">
        <h2>6. Why This Phase Is Attractive for Investors</h2>
        <p>
            This is a realistic, infrastructure-focused value proposition — not hype.
        </p>

        <h3>6.1 Solves a Real Global Problem</h3>
        <p>
            Understanding medication behaviour across languages and contexts is extremely hard and expensive.
            Phase 6 addresses this gap directly.
        </p>

        <h3>6.2 Competes With &amp; Exceeds Omada / Livongo / Huma in One Area</h3>
        <p>
            Most existing platforms focus on:
        </p>
        <ul>
            <li>English-only (mostly US)</li>
            <li>Structured inputs</li>
            <li>Nurse-led interpretation</li>
        </ul>
        <p>
            Elisence offers:
        </p>
        <ul>
            <li>Five languages from day one</li>
            <li>Zero-typing voice support</li>
            <li>Automatic structuring of free-text</li>
            <li>Jurisdiction-aware behaviour</li>
            <li>BBVP + Zero-Trust medication intelligence</li>
        </ul>
        <p>
            No competitor has all of these combined in a single engine.
        </p>

        <h3>6.3 Safe for Regulators</h3>
        <ul>
            <li>Not a medical device</li>
            <li>Not diagnosis</li>
            <li>Not direct medical advice</li>
            <li>Only structured understanding → very low legal risk</li>
        </ul>

        <h3>6.4 Essential for Future Phases</h3>
        <p>
            Phase 6 is the foundation for the drug-related intelligence powering:
        </p>
        <ul>
            <li>AHE risk models</li>
            <li>GLP-1 / obesity routes</li>
            <li>Women+ medication cross-checking</li>
            <li>Voice accessibility for blind users</li>
            <li>Government dashboards and research tools (future)</li>
        </ul>
        <p>
            Investors understand core infrastructure value.
        </p>
    </section>

    <!-- 7. LIMITATIONS -->
    <section class="card">
        <h2>7. Limitations (Honest &amp; Transparent)</h2>
        <p>
            Phase 6 does <strong>not</strong> currently:
        </p>
        <ul>
            <li>Classify all global drugs</li>
            <li>Handle all dialects in Arabic or Persian</li>
            <li>Detect drug–drug interactions</li>
            <li>Perform medical triage</li>
            <li>Provide automated dosing suggestions</li>
            <li>Replace clinicians</li>
        </ul>
        <p>
            These are intentionally excluded to avoid:
        </p>
        <ul>
            <li>High-risk MDR / FDA classification</li>
            <li>Clinical liability</li>
            <li>Unsafe or overreaching behaviour</li>
        </ul>
    </section>

    <!-- 8. SUMMARY -->
    <section class="card">
        <h2>8. One-Sentence Summary</h2>
        <p>
            Phase 6 is the multilingual, jurisdiction-aware, zero-trust
            <strong>Global Medication Brain</strong> of Elisence — a safe, auditable foundation that understands
            and structures medication behaviour across five languages, powers every major phase of the platform,
            and remains legally compliant across NHS, FDA, EU, and GCC markets.
        </p>
    </section>

</main>

</body>
</html>
